Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? Over the past ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.
They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...
StockStory.org on MSN
Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results , with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...
Oracle announced the Oracle Life Sciences AI Data Platform, a generative AI-enabled solution designed to empower pharmaceutical, medical device, research, and life sciences organizations to accelerate ...
Achieve Life Sciences is a late-stage pharma company awaiting FDA approval for Cytisinicline, a novel smoking cessation ...
Morgridge Hall opened to UW-Madison students this semester. It houses the School of Computer, Data and Information Sciences. The new building is entirely donor-funded, the second such project on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results